What is HC Wainwright’s Estimate for XENE Q1 Earnings?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Research analysts at HC Wainwright issued their Q1 2027 earnings estimates for Xenon Pharmaceuticals in a research note issued on Friday, August 7th. HC Wainwright analyst D. Tsao forecasts that the biopharmaceutical company will earn ($1.21) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $74.00 target price on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($4.92) per share.

A number of other research firms have also recently weighed in on XENE. Wall Street Zen raised Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. JPMorgan Chase & Co. increased their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. Royal Bank Of Canada dropped their price objective on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating for the company in a research report on Friday. Wells Fargo & Company reissued an “overweight” rating and issued a $69.00 target price on shares of Xenon Pharmaceuticals in a research note on Sunday, May 10th. Finally, Needham & Company LLC decreased their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Xenon Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $77.13.

Xenon Pharmaceuticals Stock Performance

XENE stock opened at $64.23 on Monday. The stock’s 50 day moving average price is $60.45 and its 200 day moving average price is $54.46. The firm has a market cap of $6.21 billion, a P/E ratio of -13.55 and a beta of 0.62. Xenon Pharmaceuticals has a 1 year low of $32.78 and a 1 year high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.05. During the same quarter in the previous year, the firm earned ($1.07) EPS.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the sale, the director directly owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the sale, the director owned 24,896 shares of the company’s stock, valued at $1,322,973.44. This trade represents a 5.04% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 2.91% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in Xenon Pharmaceuticals in the second quarter valued at approximately $454,057,000. Avoro Capital Advisors LLC raised its stake in Xenon Pharmaceuticals by 0.5% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock worth $243,124,000 after purchasing an additional 24,444 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Xenon Pharmaceuticals by 2.3% in the 1st quarter. Janus Henderson Group PLC now owns 4,175,982 shares of the biopharmaceutical company’s stock valued at $242,858,000 after purchasing an additional 91,948 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after purchasing an additional 1,435,096 shares during the last quarter. Finally, Capital International Investors grew its stake in shares of Xenon Pharmaceuticals by 7.3% during the 4th quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock valued at $153,058,000 after buying an additional 233,466 shares during the period. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.